Blockchain Registration Transaction Record

GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial

GeoVax completes release testing for GEO-MVA mpox/smallpox vaccine, advancing toward Phase 3 trial. Could address global supply gaps and enhance biodefense preparedness.

This development matters because it addresses a critical vulnerability in global health security. Mpox outbreaks in recent years have exposed gaps in vaccine supply and preparedness, while smallpox remains a bioterrorism concern. Currently, the world relies on a single manufacturer for MVA-based vaccines, creating a dangerous lack of redundancy. GeoVax's GEO-MVA vaccine could diversify supply chains, enhance national stockpiles, and improve rapid response capabilities for future outbreaks. For individuals, this means better protection against emerging infectious diseases and reduced risk in an interconnected world. For public health systems, it offers a more resilient defense infrastructure, potentially saving lives and reducing economic disruption during health crises.